These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10777146)

  • 1. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
    Phenix BN; Angel JB; Mandy F; Kravcik S; Parato K; Chambers KA; Gallicano K; Hawley-Foss N; Cassol S; Cameron DW; Badley AD
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):559-67. PubMed ID: 10777146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
    Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
    Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
    J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection.
    Badley AD; Parato K; Cameron DW; Kravcik S; Phenix BN; Ashby D; Kumar A; Lynch DH; Tschopp J; Angel JB
    Cell Death Differ; 1999 May; 6(5):420-32. PubMed ID: 10381636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
    Lucia MB; Rutella S; Leone G; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.
    Kravcik S; Magill A; Sanghvi B; Ogden R; Cameron WD; Lewis R; Yu G; Badley AD
    HIV Clin Trials; 2001; 2(2):160-70. PubMed ID: 11590524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
    Feuth T; van Baarle D; Hoepelman AI; Arends JE
    Antivir Ther; 2013; 18(8):1021-5. PubMed ID: 23732862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
    Sloand EM; Kumar PN; Kim S; Chaudhuri A; Weichold FF; Young NS
    Blood; 1999 Aug; 94(3):1021-7. PubMed ID: 10419894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
    Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
    J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
    Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
    HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.
    Moretti S; Alesse E; Marcellini S; Di Marzio L; Zazzeroni F; Parroni R; Famularo G; Boschini A; Cifone MG; De Simone C
    Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):645-65. PubMed ID: 10584202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
    Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.